Alto Neuroscience, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Alto Neuroscience, Inc. | ANRO - NYSE |
$14.00-$16.00 | $16.00 | $22.00 | 8.04 million | 2/2/2024 |
| Jefferies, TD Cowen, Stifel, William Blair | ||||||
Co-Manager(s): Baird | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-01-12 Terms Added 2024-01-29 | ||||||
Alto Neuroscience, Inc. Quote & Chart - Click for current quote - ANRO
IPO Boutique aggregates information on public companies and private companies, such as "ANRO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Alto Neuroscience, Inc. (adapted from Alto Neuroscience, Inc. prospectus):
They are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ANRO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.